Lisanti Capital Growth LLC Trims Holdings in GeneDx Holdings Corp. $WGS

Lisanti Capital Growth LLC cut its stake in GeneDx Holdings Corp. (NASDAQ:WGS) by 27.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 41,128 shares of the company’s stock after selling 15,495 shares during the quarter. GeneDx comprises about 1.3% of Lisanti Capital Growth LLC’s holdings, making the stock its 27th largest position. Lisanti Capital Growth LLC’s holdings in GeneDx were worth $5,349,000 as of its most recent filing with the SEC.

Other hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp grew its position in shares of GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in GeneDx during the fourth quarter valued at $35,000. Quarry LP boosted its stake in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after buying an additional 209 shares during the period. Gordian Capital Singapore Pte Ltd bought a new stake in GeneDx during the third quarter valued at $65,000. Finally, AlphaQuest LLC boosted its stake in GeneDx by 70.8% during the third quarter. AlphaQuest LLC now owns 1,303 shares of the company’s stock valued at $140,000 after buying an additional 540 shares during the period. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CFO Kevin Feeley sold 392 shares of the business’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $65.19, for a total value of $25,554.48. Following the completion of the sale, the chief financial officer owned 34,942 shares of the company’s stock, valued at approximately $2,277,868.98. The trade was a 1.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Keith A. Meister bought 46,273 shares of the stock in a transaction dated Friday, May 15th. The stock was bought at an average cost of $38.91 per share, with a total value of $1,800,482.43. Following the purchase, the director owned 4,784,570 shares in the company, valued at $186,167,618.70. The trade was a 0.98% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 2,225,941 shares of company stock valued at $95,494,951 and sold 104,028 shares valued at $7,377,165. Corporate insiders own 29.60% of the company’s stock.

GeneDx Trading Down 0.0%

Shares of WGS stock opened at $47.31 on Friday. The company has a quick ratio of 2.95, a current ratio of 3.09 and a debt-to-equity ratio of 0.38. The business has a 50-day moving average price of $59.72 and a two-hundred day moving average price of $98.90. GeneDx Holdings Corp. has a 12-month low of $32.21 and a 12-month high of $170.87. The firm has a market cap of $1.40 billion, a P/E ratio of -17.65 and a beta of 2.06.

GeneDx (NASDAQ:WGS) last issued its quarterly earnings results on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The firm had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. During the same period last year, the firm earned ($0.23) EPS. Equities analysts anticipate that GeneDx Holdings Corp. will post -1 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently issued reports on WGS shares. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings raised GeneDx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. BTIG Research dropped their price objective on GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Craig Hallum reissued a “buy” rating and set a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Finally, Wells Fargo & Company reissued an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a research note on Tuesday, May 5th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.43.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.